These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 3083210)
1. Studies of aldose reductase using neuronal cell culture and ligated rat sciatic nerve. Chandler CE; Miller LJ Metabolism; 1986 Apr; 35(4 Suppl 1):71-7. PubMed ID: 3083210 [TBL] [Abstract][Full Text] [Related]
2. Slow component-a of axonal transport, nerve myo-inositol, and aldose reductase inhibition in streptozocin-diabetic rats. Tomlinson DR; Sidenius P; Larsen JR Diabetes; 1986 Apr; 35(4):398-402. PubMed ID: 2420664 [TBL] [Abstract][Full Text] [Related]
3. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy. Shindo H; Tawata M; Aida K; Onaya T J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506 [TBL] [Abstract][Full Text] [Related]
4. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats. Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043 [TBL] [Abstract][Full Text] [Related]
5. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats. Mayer JH; Tomlinson DR Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336 [TBL] [Abstract][Full Text] [Related]
6. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy. Mizuno K; Kato N; Makino M; Suzuki T; Shindo M J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874 [TBL] [Abstract][Full Text] [Related]
7. Treatment with an aldose reductase inhibitor can reduce the susceptibility of fast axonal transport following nerve compression in the streptozotocin-diabetic rat. Dahlin LB; Archer DR; McLean WG Diabetologia; 1987 Jun; 30(6):414-8. PubMed ID: 2445613 [TBL] [Abstract][Full Text] [Related]
8. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats. Yue DK; Hanwell MA; Satchell PM; Turtle JR Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173 [TBL] [Abstract][Full Text] [Related]
9. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819 [TBL] [Abstract][Full Text] [Related]
10. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil. Tomlinson DR; Moriarty RJ; Mayer JH Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576 [TBL] [Abstract][Full Text] [Related]
11. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats. Schmidt RE; Plurad SB; Sherman WR; Williamson JR; Tilton RG Diabetes; 1989 May; 38(5):569-79. PubMed ID: 2497038 [TBL] [Abstract][Full Text] [Related]
12. Increased nerve polyol levels in experimental diabetes and their reversal by Sorbinil. Whiting PH; Ross IS Br J Exp Pathol; 1988 Oct; 69(5):697-702. PubMed ID: 3143396 [TBL] [Abstract][Full Text] [Related]
13. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. Ashizawa N; Yoshida M; Sugiyama Y; Akaike N; Ohbayashi S; Aotsuka T; Abe N; Fukushima K; Matsuura A Jpn J Pharmacol; 1997 Feb; 73(2):133-44. PubMed ID: 9074947 [TBL] [Abstract][Full Text] [Related]
14. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats. Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645 [TBL] [Abstract][Full Text] [Related]
15. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux. Matsumoto T; Ono Y; Kurono M; Kuromiya A; Nakamura K; Bril V J Pharmacol Sci; 2009 Feb; 109(2):203-10. PubMed ID: 19212096 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor. Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756 [TBL] [Abstract][Full Text] [Related]
17. Impaired nerve regeneration in streptozotocin-diabetic rats. Effects of treatment with an aldose reductase inhibitor. Ekström AR; Tomlinson DR J Neurol Sci; 1989 Nov; 93(2-3):231-7. PubMed ID: 2531788 [TBL] [Abstract][Full Text] [Related]
18. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats. Peterson MJ; Sarges R; Aldinger CE; MacDonald DP Metabolism; 1979 Apr; 28(4 Suppl 1):456-61. PubMed ID: 122297 [TBL] [Abstract][Full Text] [Related]
19. Effect of a new aldose reductase inhibitor, 8'-chloro-2',3'-dihydrospiro [pyrrolidine-3,6'(5'H)-pyrrolo[1,2,3-de] [1,4]benzoxazine]-2,5,5'- trione (ADN-138), on delayed motor nerve conduction velocity in streptozotocin-diabetic rats. Hirata Y; Fujimori S; Okada K Metabolism; 1988 Feb; 37(2):159-63. PubMed ID: 2828821 [TBL] [Abstract][Full Text] [Related]
20. Adenosine triphosphatase activity in sciatic nerve tissue of streptozocin-induced diabetic rats with and without high dietary sucrose: effect of aldose reductase inhibitors. Sredy J; Flam BR; Sawicki DR Proc Soc Exp Biol Med; 1991 Jun; 197(2):135-43. PubMed ID: 1851565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]